US Patent 12,186,306 (Cystic Fibrosis): Scope of Claims and Patent-Landscape Implications
What does US Patent 12,186,306 claim, at the method-of-use level?
US 12,186,306 claims a daily-treatment method for cystic fibrosis (CF) defined by a three-component daily regimen with fixed daily doses and a specified solid-form identity for Compound II (the “calcium salt hydrate Form D”). The claims are structured to lock both (i) regimen dose and (ii) Compound II polymorph/crystal-hydrate form while using patient-genotype guardrails tied to CFTR F508del and specified mutation sets.
Core regimen dose structure (claims 1 and 2)
Both independent claims require daily administration of three compounds:
- Compound I: 250 mg/day (or a pharmaceutically acceptable salt equivalent)
- Compound II: 21.24 mg/day of Compound II calcium salt hydrate Form D
- Compound III: 100 mg/day (or a pharmaceutically acceptable salt equivalent)
Claim 1: recites dose with “Compound I: or an equivalent amount… salt thereof” and “Compound III: or an equivalent amount… salt thereof,” while Compound II is fixed to Form D.
Claim 2: narrows to “daily administration” with explicit dosing amounts and specifies Compound III as “(Compound III),” without the “salt equivalent” phrasing for Compound III present in claim 1 (as provided).
How is regimen delivery constrained? (claims 3–5)
The claims cover both formulation architectures:
- Claim 3: Compounds I, II, III are administered in separate compositions.
- Claim 4: Compounds I, II, III are administered in a single composition.
- Claim 5: “two compositions once daily,” with a split regimen:
- 125 mg Compound I
- 10.62 mg Compound II calcium salt hydrate Form D
- 50 mg Compound III
- repeated twice per day (implied by “two compositions once daily” and “each composition comprising” the half-dose; the claim language as provided describes the per-composition content).
From a design-around perspective, claims 3–5 remove a common workaround: changing whether the three actives are co-formulated or dosed separately.
How does the claim set constrain patient population (genotype-based scope)?
The method claims include genotype qualifiers to define who qualifies for the claimed treatment:
Primary F508del category (claim 6)
Claim 6 limits the method of claim 1 to patients who are:
- homozygous for F508del, or
- F508del/minimal function
- F508del/gating
- F508del/residual function genotypes
Heterozygous with one F508del copy (claims 7–10)
- Claim 7: patient is heterozygous with one F508del CFTR mutation.
- Claim 8: one additional CFTR mutation selected from a long list (as provided).
- Claim 9: another long list, with special language: certain listed mutations are complex/compound mutations where a single allele contains multiple mutations existing independently of other allele mutations.
- Claim 10: again lists an expanded mutation set (as provided), including the long list variants and references to complex/compound mutations.
Practical consequence: the claimed use is not “CF broadly”; it is CF defined by CFTR mutation class plus specific mutation lists. This matters for payer coverage, marketing claims, and enforcement because infringement requires both:
1) the dosing regimen and
2) the patient’s CFTR genotype falling within the claim’s selected categories.
How does Compound II Form D get locked down (solid-state scope)?
The strongest technical lock is that Compound II is “calcium salt hydrate Form D” and is further defined through XRPD, crystal system/space group/unit cell, and 13C ssNMR peak sets in dependent claims.
XRPD signature constraints (claims 11–15)
Claim 11: requires XRPD signals at:
- 6.1 ± 0.2° 2θ
- 16.2 ± 0.2° 2θ
- 22.8 ± 0.2° 2θ
Claim 12: adds optional/additional peaks:
- must include the claim 11 three peaks, plus one or more of:
- 5.5 ± 0.2
- 15.5 ± 0.2
- 19.7 ± 0.2
- 21.5 ± 0.2
- 22.1 ± 0.2
- 23.0 ± 0.2
- 27.6 ± 0.2
Claim 13: includes 6.1 / 16.2 / 22.8 plus 27.6 ± 0.2 only (as provided).
Claim 14: includes 6.1 / 15.5 / 16.2 / 19.7 / 22.8 / 27.6.
Claim 15: allows a “substantially similar to FIG. 5” XRPD.
Crystallography identity (claim 16)
Claim 16 further defines Form D by:
- triclinic crystal system
- P1 space group
- unit cell dimensions measured at 100 K (Bruker diffractometer, Cu Kα, λ = 1.5478 Å):
- a = 12.78 ± 0.01 Å
- α = 64.93 ± 0.02°
- b = 16.64 ± 0.01 Å
- β = 75.10 ± 0.02°
- c = 18.19 ± 0.01 Å
- γ = 68.22 ± 0.02°
13C solid-state NMR constraints (claims 17–20)
Claim 17: requires one or more peaks selected from:
- 130.2 ± 0.2 ppm
- 125.6 ± 0.2 ppm
- 35.0 ± 0.2 ppm
Claim 18: expands candidate peak sets to any one or more of:
- 179.8 ± 0.2
- 130.2 ± 0.2
- 125.6 ± 0.2
- 120.9 ± 0.2
- 55.2 ± 0.2
- 44.3 ± 0.2
- 35.0 ± 0.2
- 1.6 ± 0.2
Claim 19: imposes a two-group structure:
- at least one peak from (a) 130.2 ± 0.2 / 125.6 ± 0.2 / 35.0 ± 0.2
- and at least one peak from (b) 176.9 ± 0.2 / 160.9 ± 0.2 / 142.0 ± 0.2 / 98.6 ± 0.2
Claim 20: permits “substantially similar to FIG. 6” 13C ssNMR spectrum.
Purity thresholds for Form D (claims 21–22)
Claims 21–22 require high proportions of Form D:
- Claim 21: at least 85% of Compound II is Form D
- Claim 22: at least 95% of Compound II is Form D
Enforcement implication: even if a manufacturer uses “a calcium salt hydrate,” infringement for dependent claim scope can hinge on whether the solid-state material meets the specified Form D XRPD/NMR identity and is present at or above the threshold.
What is the practical claim coverage structure? (claim scope map)
The claim set operates like a layered net:
1) Regimen: fixed daily doses for Compound I/II/III (method-of-use)
2) Patient genotype: CFTR categories and mutation lists (method-of-use)
3) Solid form: Form D identity for Compound II (dependent limitations)
4) Measurement hooks: XRPD angles, crystallography parameters, 13C ssNMR peaks (dependent limitations)
5) Compositional purity: 85% or 95% Form D thresholds (dependent limitations)
6) Administration architecture: single vs separate vs split daily compositions (dependent limitations)
Claim dependency summary
| Claim |
Core regimen |
Genotype limitation |
Form D definition |
Administration format |
| 1 |
Yes: 250 / 21.24 / 100 mg |
Yes (via claim 6–10 depending) |
Yes (Form D) |
Separate or single depends on 3–5 |
| 2 |
Yes: 250 / 21.240 / 100 mg |
Yes (via claim 6–10 depending) |
Yes (Form D) |
Separate or single depends on 3–5 |
| 3 |
Yes |
Optional (if combined with 6–10) |
Yes |
Separate compositions |
| 4 |
Yes |
Optional |
Yes |
Single composition |
| 5 |
Yes (split) |
Optional |
Yes |
Two compositions once daily (half-dose each) |
| 6–10 |
Yes |
Yes |
Yes |
N/A |
| 11–15 |
Yes |
Optional |
XRPD |
N/A |
| 16 |
Yes |
Optional |
Crystallography |
N/A |
| 17–20 |
Yes |
Optional |
13C ssNMR |
N/A |
| 21–22 |
Yes |
Optional |
Purity % |
N/A |
Where does this land in the broader US CF patent landscape?
On the US patent side, patents like 12,186,306 typically sit in a crowded CF space where multiple layers coexist:
- Drug substance patents (compound identities, salts, polymorphs/hydrates)
- Formulation patents (dosage forms, coatings, granulations, combination tablets/capsules)
- Method-of-use patents (patient genotype, dosing regimen, and clinical endpoints)
- Combination regimen patents (multi-agent schedules, fixed-dose combos, co-administration architectures)
- Solid-state form patents (XRPD/NMR-defined polymorphs/hydrates and purity thresholds)
This particular filing is most enforceable when a generic or follow-on drug would need to replicate:
1) the daily multi-compound regimen with the exact dose levels and
2) the specific solid-state Form D material for Compound II and
3) a targeted CFTR-genotype population.
Even where a follow-on candidate has the same active(s) and dosing, the Form D identity and purity thresholds can create a practical differentiation barrier. Even where solid form is matched, the genotype limitations can limit infringement coverage to labeled or trial-population uses.
How strong is the design-around surface? (what changes could avoid infringement)
Within the constraints visible in the claims provided, the following design variables are directly addressed or made hard:
Administration format
- The claims explicitly cover single composition and separate compositions and a two-composition once-daily split (claims 3–5).
- A design-around based solely on changing co-packaging or tablet vs capsule structure is unlikely to escape claim coverage.
Solid-state identity
- Form D is defined by multiple orthogonal characterization methods:
- XRPD signal positions with ±0.2° tolerances (claims 11–15)
- crystal system and space group plus unit cell parameters at 100 K (claim 16)
- 13C ssNMR peak sets (claims 17–20)
- Form D proportion thresholds (≥85% and ≥95%) (claims 21–22)
- A design-around based on using a different polymorph/hydrate would only work if it avoids meeting these Form D characterization requirements and purity thresholds for Form D.
Patient-genotype selection
- Claims 6–10 impose targeted CFTR categories and mutation lists.
- A design-around based on treating broader CF populations would not neutralize infringement for the qualified genotypes if all method elements are met.
What is the “scope vs claims” bottom line for business decisions?
US 12,186,306 is not a broad “CF treatment” claim set. It is a constrained method-of-use patent centered on:
- Fixed daily dosing of a 3-compound combination (Compound I / Compound II Form D / Compound III)
- A genotype-defined patient population focused on F508del and enumerated mutation sets
- Compound II calcium salt hydrate Form D defined by XRPD + crystallography + 13C ssNMR and Form D purity
That combination makes it materially harder to design around using:
- delivery architecture changes,
- salt form changes for Compound II without matching Form D,
- or shifting to adjacent CF populations.
Key Takeaways
- Claim scope is anchored on a fixed daily triple regimen: 250 mg Compound I, 21.24 mg Compound II calcium salt hydrate Form D, and 100 mg Compound III (claims 1–2).
- Delivery format is broad: separate compositions, single composition, and a two-composition once-daily split all fall within the claim set (claims 3–5).
- Patient eligibility is genotype-limited: F508del categories and detailed CFTR mutation lists are required for method coverage (claims 6–10).
- Compound II Form D is heavily characterized: XRPD signal sets, triclinic P1 unit cell parameters at 100 K, and 13C ssNMR peak sets plus “substantially similar” fallback language (claims 11–20).
- Purity thresholds raise practical enforcement leverage: Form D must be present at ≥85% or ≥95% depending on the dependent claim invoked (claims 21–22).
FAQs
-
Does US 12,186,306 require all three compounds to be administered daily?
Yes. Claims 1 and 2 require daily administration of Compound I (250 mg), Compound II calcium salt hydrate Form D (21.24 mg), and Compound III (100 mg).
-
Can a product avoid the patent by changing whether the actives are in one pill or separate pills?
The claim set covers both single composition and separate compositions, plus a two-composition once-daily split, so changing only packaging structure is unlikely to avoid scope (claims 3–5).
-
Is Compound II’s form limited only by labeling, or is it tied to analytical specs?
It is tied to analytical specs: XRPD angles, crystallography (triclinic P1, unit cell at 100 K), and 13C ssNMR peak sets, with “substantially similar” alternatives (claims 11–20).
-
Do the claims cover any cystic fibrosis patient?
No. The method is limited to CFTR genotype categories and enumerated mutation lists tied to F508del (claims 6–10).
-
What material purity limits are imposed for Compound II Form D?
Dependent claims require ≥85% Form D (claim 21) or ≥95% Form D (claim 22) of Compound II.
References
- US Patent 12,186,306. Claims as provided by user content (claims 1–22).
